Identifying genes that affect prostate cancer progression
Identify Genes/Pathways Responsible for Progression From Low Risk to Higher Risk Prostate Cancer-A New Strategy for Prostate Cancer Prevention
National Taiwan University Hospital · NCT03789253
This study is trying to find out which genes might influence how low-risk prostate cancer changes into more serious forms, using samples from patients who have been closely monitored since 2013.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 40 Years to 100 Years |
| Sex | Male |
| Sponsor | National Taiwan University Hospital (other) |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Taipei) |
| Trial ID | NCT03789253 on ClinicalTrials.gov |
What this trial studies
This observational study aims to identify the genetic factors and pathways that contribute to the progression of low-risk prostate cancer to higher-risk forms. Conducted at the National Taiwan University Hospital, it utilizes a large cohort of patients who have undergone active surveillance or watchful waiting since 2013. By comparing genetic changes in patients who experience disease progression with those who do not, the study seeks to uncover key biomarkers that could help predict and manage prostate cancer progression. The research involves analyzing serial biopsy samples to correlate genetic alterations with cancer phenotypes and treatment outcomes.
Who should consider this trial
Good fit: Ideal candidates include men with a confirmed diagnosis of low-risk prostate cancer who are undergoing active surveillance at the National Taiwan University Hospital.
Not a fit: Patients who have received prior systemic chemotherapy, pelvic radiotherapy, or androgen deprivation therapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved management strategies for low-risk prostate cancer, potentially reducing unnecessary treatments and enhancing patient quality of life.
How similar studies have performed: While there have been studies exploring genetic factors in prostate cancer, this specific approach of comparing progressive and non-progressive cases in a large cohort is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Historically or cytologically confirmed adenocarcinoma of prostate. 2. Have or ever received active Surveillance as the main conservative management at NTUH (National Taiwan University Hospital). 3. Have or will receive prostate biopsy to confirm tumor progression after the diagnosis of prostate cancer. Exclusion Criteria: 1. Have received systemic chemotherapy, pelvic radiotherapy or androgen deprivation therapy (ADT) before the obtainment of pathological specimen from prostate operation or biopsy. 2. Subjects who disagree with signing the informed consent.
Where this trial is running
Taipei
- National Taiwan University — Taipei, Taiwan (RECRUITING)
Study contacts
- Principal investigator: Yeong-Shiau Pu, PhD — National Taiwan University
- Study coordinator: Yeong-Shiau Pu, PhD
- Email: yspu@ntu.edu.tw
- Phone: 886-2-23123456
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Prostate Cancer Stage I, active surveillance, microarray, latent, GSEA, latent